Homozygous Familial Hypercholesterolemia
Metabolic·MeSH: Homozygous Familial Hypercholesterolemia
Prevalence
0.5 / 100K
9 drugs in development·5 companies·5 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Evkeeza | Ultragenyx Pharmaceutical Inc. (RARE) |
Phase 3(3)
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| aem-28 | Capstone Holding Corp. (CAPS) |
Preclinical(1)
| Drug | Company |
|---|---|
| aem-28-08 | Capstone Holding Corp. (CAPS) |
Phase 4(1)
| Drug | Company |
|---|---|
| Inclisiran | Novartis AG (NVS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Homozygous Familial Hypercholesterolemia?
BioSniper tracks 9 drugs in development for Homozygous Familial Hypercholesterolemia across 5 companies.
How many clinical trials target Homozygous Familial Hypercholesterolemia?
There are 5 clinical trials targeting Homozygous Familial Hypercholesterolemia tracked by BioSniper.
What is the prevalence of Homozygous Familial Hypercholesterolemia?
The estimated prevalence of Homozygous Familial Hypercholesterolemia is approximately 0.5 per 100,000 population.
Deep-dive into Homozygous Familial Hypercholesterolemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis